Dantrolene and ryanodine receptors in COVID‐19: The daunting task and neglected warden

Abstract

AbstractDantrolene (DTN) is a ryanodine receptor (RyR) antagonist that inhibits Ca2+ release from stores in the sarcoplasmic reticulum. DTN is mainly used in the management of malignant hyperthermia. RyRs are highly expressed in immune cells and are involved in different viral infections, including severe acute respiratory syndrome coronavirus type 2 (SARS‐CoV‐2), because Ca2+ is necessary for viral replication, maturation and release. DTN can inhibit the proliferation of SARS‐CoV‐2, indicating its potential role in reducing entry and pathogenesis of SARS‐CoV‐2. DTN may increase clearance of SARS‐CoV‐2 and promote coronavirus disease 2019 (COVID‐19) recovery by shortening the period of infection. DTN inhibits N‐methyl‐D‐aspartate (NMDA) mediated platelets aggregations and thrombosis. Therefore, DTN may inhibit thrombosis and coagulopathy in COVID‐19 through suppression of platelet NMDA receptors. Moreover, DTN has a neuroprotective effect against SARS‐CoV‐2 infection‐induced brain injury through modulation of NMDA receptors, which are involved in excitotoxicity, neuronal injury and the development of neuropsychiatric disorders. In conclusion, DTN by inhibiting RyRs may attenuate inflammatory disorders in SARS‐CoV‐2 infection and associated cardio‐pulmonary complications. Therefore, DNT could be a promising drug therapy against COVID‐19. Preclinical and clinical studies are warranted in this regards.